All News

IPF.lancet.jpg

ILD Patients At Risk for Autoimmune Disease

d Jack Cush, MD

Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Women Take Over Rheumatology (10.4.19)

d Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.

Read Article
OP_0.jpg

ASBMR Recommendations on Secondary Fracture Prevention

d Jack Cush, MD

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Read Article
young%20doctors.jpg (keep)

Increasingly Women are Choosing Subspecialty Careers

d Jack Cush, MD

JAMA Internal Medicine has an analysis of the growing trend of more women enrolling in medical schools in the last few decades, such that more than half of US Med school matriculants in 2017 were women.  Also in 2017, 42% of residents in internal medicine were women.  The reported analy

Read Article
PsA.Hands_.jpg

Ixekizumab vs. Adalimumab in Psoriatic Arthritis

d Jack Cush, MD

The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.

Read Article
Looking forward to giving plenary talk at #ACR2019 at 11AM Sunday on practical aspects of vaccines(flu/pneumo/VZV) for autoimmune pts @paijournal @IDSA @RheumNow @HealioRheum @AdamJBrownMD @ELittlejohnDO @RulaHajjAliMD https://t.co/UIYBIBDeSe

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)

Get the FREE RheumaKnowledgy Card - a pocket guide/aid to the diagnosis, testing and Rx of Rheumatologic, autoimmune and other MSK complaints. https://t.co/oMa3qzh7xt

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM: Synovial Chondromatosis. A 46-year-old woman with rheumatoid arthritis presented with pain and swelling in both knees. Radiographic findings were consistent with synovial chondromatosis. https://t.co/9jMzE0fuNE

Links:

Dr. John Cush RheumNow ( View Tweet)

N. Zealand study shows their cost of knee OA was $200 million in 2013; and without any changes in the standards of care, this isprojected to increase to $370 million by 2038. (includes an additional 4,000 TKRs per year by 2038). https://t.co/B1awh1ky1B

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm

Links:

Dr. John Cush RheumNow ( View Tweet)

Might Vioxx make a backdoor comeback? 2017 Vioxx went off patent, now a small pharma has applied to the FDA for orphan drug approval of rofecoxib (& etoricoxib) to treat hemophiliac arthropathy (large unmet need). Say it aint so! https://t.co/kENHHhcyIT https://t.co/QpDNiaCZyz

Links:

Dr. John Cush RheumNow ( View Tweet)

Choi and colleagues have shown that allopurinol-associated severe cutaneous adverse reactions are higher with Heart (RR 1.44) and Renal (11 fold) disease. Initating low-dosage allopurinol may substantially mitigate this risk. https://t.co/gyj7Xn3uhx

Links:

Dr. John Cush RheumNow ( View Tweet)

MotherToBaby Pregnancy Study in 528 RA pts has shown oral steroid use yields a dose dependent risk of pre-term birth. PTB was increased high dose (RR: 4.77) and medium dose (aRR: 1.81) OCS in the 1st 139 gestational days; DMARDs/biologics were not https://t.co/cuggovK8eL

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of retail pharmacies and drug costs show that, compared to large chain pharmacies, big box was 48% cheaper, followed by grocery-based (18% cheaper), next small chain (51% higher), and independent pharmacies (61% higher) https://t.co/jlQnNboiAR

Links:

Dr. John Cush RheumNow ( View Tweet)

Approximately 20–30% of IBD patients will develop spondyloarthritis. Using a survey tool on 244 IBD pts they found 21% with sufficient criteria to suspect SpA - Other risk factors included being female, Crohn's, prior DMARD or biologic drug use. https://t.co/9Ail7syLmB

Links:

Dr. John Cush RheumNow ( View Tweet)

One of my favorite things about writing "health humanities" pieces for journals are the gracious, thoughtful, insightful notes I get from fellow docs. This one arrived in my inbox this AM. Humbling in its perfection. In response to this article: https://t.co/9uPvPDOPAI https://t.co/85usMOPqlb

Links:

Adam Cifu adamcifu ( View Tweet)
Felt the need to update my 10 commandments. Fortunately, on twitter, commandments are not written in stone. https://t.co/Rt9YDW8lFh
Adam Cifu adamcifu ( View Tweet)
"Physicians don’t hate technology – they have smartphones, fitness trackers and tablets just like everyone else – what they hate is bad technology." Truth. #fightburnout https://t.co/qTG0jZFtDL

Links:

Gabe Charbonneau, MD gabrieldane ( View Tweet)

Survey for Rheumatologists - You would use an MRI in an RA to assess what?

Dr. John Cush RheumNow ( View Tweet)

Kaiser study of 1956 SLE patients shows only 58% of were adherent (≥ 80%) to hydroxychloroquine; not predicted by the Rheum, hospital or socioeconomics. Risk factors for nonadherence included age, being white, # of Rheum visits/yr. https://t.co/qRdJRGvRAr

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×